Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination
| Autor: | Kazuhiro Toyoda, Takeo Hayashi, Eiichi Ogawa, Koji Takayama, Satoshi Hiramine |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Hepatology business.industry Proportional hazards model Hepatitis C virus Fatty liver Hazard ratio Gastroenterology Hepatitis C medicine.disease medicine.disease_cause digestive system diseases 03 medical and health sciences 0302 clinical medicine Hepatocellular carcinoma Internal medicine medicine 030211 gastroenterology & hepatology Pharmacology (medical) 030212 general & internal medicine Steatosis Steatohepatitis business |
| Zdroj: | Alimentary Pharmacology & Therapeutics. 52:866-876 |
| ISSN: | 0269-2813 |
| DOI: | 10.1111/apt.15976 |
| Popis: | BACKGROUND A strong association between chronic hepatitis C (CHC) and hepatic steatosis has been reported. However, the influence of steatohepatitis on hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) elimination remains unclear. AIM To evaluate the development of HCC after HCV cure using a new steatohepatitis-related biomarker. METHODS This cohort study analysed the prospective database of 290 CHC patients without a history of HCC who achieved HCV elimination by direct-acting antivirals. We calculated the FibroScan-aspartate aminotransferase (FAST) score 12 weeks after the end of treatment (pw12). The risk of HCC was analysed using the multivariable Cox proportional hazard model. RESULTS HCV genotype (GT)1 was most prevalent at 72.4%, followed by GT2 (26.6%). Median follow-up period was 4.2 years (IQR 3.1-4.5). The cumulative HCC incidence for a FAST score ≥ 0.35 was significantly higher than that for a FAST score |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |